Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions

ACS Chemical Biology

Volumn 8, Issue 12, 2013, Pages 2660-2668

  Aldred, Katie J ^a   Schwanz, Heidi A ^b   Li, Gangqin ^b   McPherson, Sylvia A ^c   Turnbough Jr , Charles L ^c   Kerns, Robert J ^b   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CP 115 955; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ETOPOSIDE; METAL ION; MOXIFLOXACIN; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS ANTHRACIS; CROSS REACTION; DNA CLEAVAGE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; MOLECULAR INTERACTION; MUTATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIGENS, NEOPLASM; BACILLUS ANTHRACIS; CATIONS, DIVALENT; DNA CLEAVAGE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA, BACTERIAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; KINETICS; MAGNESIUM; MUTATION; QUINAZOLINONES; QUINOLONES; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 84890834354     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400592n     Document Type: Article

References (46)

1. Hooper, D. C. (1998) Clinical applications of quinolones Biochim. Biophys. Acta 1400, 45-61
2. Hooper, D. C. (2001) Mechanisms of action of antimicrobials: focus on fluoroquinolones Clin. Infect. Dis. 32 (Suppl. 1) S9-S15
3. Linder, J. A., Huang, E. S., Steinman, M. A., Gonzales, R., and Stafford, R. S. (2005) Fluoroquinolone prescribing in the United States: 1995 to 2002 Am. J. Med. 118, 259-268
4. Andriole, V. T. (2005) The quinolones: past, present, and future Clin. Infect. Dis. 41 (Suppl. 2) S113-119
5. Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., and Zhao, X. (2009) Quinolones: action and resistance updated Curr. Top. Med. Chem. 9, 981-998
6. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17, 421-433
7. Hooper, D. C. (1999) Mode of action of fluoroquinolones Drugs 58 (Suppl. 2) 6-10
8. Anderson, V. E. and Osheroff, N. (2001) Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde Curr. Pharm. Des. 7, 337-353
9. Drlica, K., Malik, M., Kerns, R. J., and Zhao, X. (2008) Quinolone-mediated bacterial death Antimicrob. Agents Chemother. 52, 385-392
10. Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., and Keim, P. (2003) In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin Antimicrob. Agents Chemother. 47, 2362-2365
11. Grohs, P., Podglajen, I., and Gutmann, L. (2004) Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations Antimicrob. Agents Chemother. 48, 3024-3027
12. Bast, D. J., Athamna, A., Duncan, C. L., de Azavedo, J. C., Low, D. E., Rahav, G., Farrell, D., and Rubinstein, E. (2004) Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance J. Antimicrob. Chemother. 54, 90-94
13. Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., and Zechiedrich, L. (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates Antimicrob. Agents Chemother. 53, 235-241
14. Levine, C., Hiasa, H., and Marians, K. J. (1998) DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities Biochim. Biophys. Acta 1400, 29-43
15. Champoux, J. J. (2001) DNA topoisomerases: structure, function, and mechanism Annu. Rev. Biochem. 70, 369-413
16. Deweese, J. E., Osheroff, M. A., and Osheroff, N. (2009) DNA topology and topoisomerases: teaching a ″knotty″ subject Biochem. Mol. Biol. Educ. 37, 2-10
17. Gentry, A. C. and Osheroff, N. (2013) DNA topoisomerases: type II, in Encyclopedia of Biological Chemistry, pp 163-168, Elsevier Inc., New York.
18. Drlica, K. and Zhao, X. (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones Microbiol. Mol. Biol. Rev. 61, 377-392
19. Yoshida, H., Kojima, T., Yamagishi, J., and Nakamura, S. (1988) Quinolone-resistant mutations of the gyrA gene of Escherichia coli Mol. Gen. Genet. 211, 1-7
20. Cullen, M. E., Wyke, A. W., Kuroda, R., and Fisher, L. M. (1989) Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones Antimicrob. Agents Chemother. 33, 886-894
21. Li, Z., Deguchi, T., Yasuda, M., Kawamura, T., Kanematsu, E., Nishino, Y., Ishihara, S., and Kawada, Y. (1998) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis Antimicrob. Agents Chemother. 42, 3293-3295
22. Aldred, K. J., McPherson, S. A., Wang, P., Kerns, R. J., Graves, D. E., Turnbough, C. L., Jr., and Osheroff, N. (2012) Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance Biochemistry 51, 370-381
23. Aldred, K. J., McPherson, S. A., Turnbough, C. L., Jr., Kerns, R. J., and Osheroff, N. (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance Nucleic Acids Res. 41, 4628-4639
24. Marshall, A. J. and Piddock, L. J. (1994) Interaction of divalent cations, quinolones and bacteria J. Antimicrob. Chemother. 34, 465-483
25. Turel, I. (2002) The interactions of metal ions with quinolone antibacterial agents Coord. Chem. Rev. 232, 27-47
26. Serafin, A. and Stańczak, A. (2009) The complexes of metal ions with fluoroquinolones Russ. J. Coord. Chem. 35, 81-95
27. Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., Shillings, A. J., Gwynn, M. N., and Bax, B. D. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance Nat. Struct. Mol. Biol. 17, 1152-1153
28. Huband, M. D., Cohen, M. A., Zurack, M., Hanna, D. L., Skerlos, L. A., Sulavik, M. C., Gibson, G. W., Gage, J. W., Ellsworth, E., Stier, M. A., and Gracheck, S. J. (2007) In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups Antimicrob. Agents Chemother. 51, 1191-1201
29. German, N., Malik, M., Rosen, J. D., Drlica, K., and Kerns, R. J. (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones Antimicrob. Agents Chemother. 52, 3915-3921
30. Pan, X. S., Gould, K. A., and Fisher, L. M. (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV Antimicrob. Agents Chemother. 53, 3822-3831
31. Oppegard, L. M., Streck, K. R., Rosen, J. D., Schwanz, H. A., Drlica, K., Kerns, R. J., and Hiasa, H. (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones Antimicrob. Agents Chemother. 54, 3011-3014
32. Malik, M., Marks, K. R., Mustaev, A., Zhao, X., Chavda, K., Kerns, R. J., and Drlica, K. (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis Antimicrob. Agents Chemother. 55, 2335-2343
33. Hammonds, T. R., Foster, S. R., and Maxwell, A. (2000) Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIα by selective mutagenesis J. Mol. Biol. 300, 481-491
34. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage J. Biol. Chem. 266, 14585-14592
35. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., and Osheroff, N. (1992) Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group Antimicrob. Agents Chemother. 36, 751-756
36. Elsea, S. H., Osheroff, N., and Nitiss, J. L. (1992) Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast J. Biol. Chem. 267, 13150-13153
37. Elsea, S. H., McGuirk, P. R., Gootz, T. D., Moynihan, M., and Osheroff, N. (1993) Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential Antimicrob. Agents Chemother. 37, 2179-2186
38. Hande, K. R. (1998) Etoposide: four decades of development of a topoisomerase II inhibitor Eur. J. Cancer 34, 1514-1521
39. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II Biochim. Biophys. Acta 1400, 173-184
40. Holden, J. A. (2001) DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic Curr. Med. Chem. Anticancer Agents 1, 1-25
41. Baldwin, E. L. and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer Curr. Med. Chem. Anticancer Agents 5, 363-372
42. Kim, M.-K. and Nightingale, C. H. (2000) Pharmacokinetics and pharmacodynamics of the fluoroquinolones, in The Quinolones (Andriole, V. T., Ed.) 3rd ed., pp 169-202, Academic Press, San Diego.
43. Dong, S., McPherson, S. A., Wang, Y., Li, M., Wang, P., Turnbough, C. L., Jr., and Pritchard, D. G. (2010) Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis J. Bacteriol. 192, 5053-5062
44. Worland, S. T. and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae J. Biol. Chem. 264, 4412-4416
45. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints Biochemistry 36, 5934-5939
46. Fortune, J. M. and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage J. Biol. Chem. 273, 17643-17650